Table 4.
Maintenance regimens
| Author | Regimen | Duration | PFS | Longer OS compared to control |
|---|---|---|---|---|
| Spencer (39) | Thalidomide/prednisone | 12 mos | 42% @ 3 yrs | yes |
| Attal (38) | Thalidomide/Pamidronate | Until PD | 37% @ 5 yrs | no |
| Barlogie (21) | Thalidomide | Until PD | 57% @ 5 yrs | no |
| Lokhorst (22) | Thalidomide | Until PD | Median 34 mos | no |
| Morgan (41) | Thalidomide | Until PD | Median 23 mos | no |
| Stewart (40) | Thalidomide | Until PD | Median 28 mos | no |
| Attal (42) | Lenalidomide | Until PD | Median 41 mos | no |
| McCarthy (43) | Lenalidomide | Until PD | Median 48 mos | yes |
| Sonneveld (26) | Bortezomib | 2 yrs | Median 36 mos | yes |
PD = progressive disease; PFS = progression-free survival; OS = overall survival